Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea

PHASE4RecruitingINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

January 9, 2020

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
Irritable Bowel SyndromeIrritable Bowel Syndrome With Diarrhea
Interventions
DRUG

Rifaximin

Rifaximin will be given during weeks 2-4

DEVICE

Glucose and lactulose hydrogen breath testing

Subjects will undergo glucose and lactulose hydrogen breath tests for Small Intestinal Bacterial Overgrowth (SIBO) on consecutive days using a commercially available home base kits (Glucose Hydrogen Breath Test Collection Kit and Lactulose Hydrogen Breath Test Collection Kit for SIBO from Commonwealth Diagnostic International) prior to Rifaximin treatment and at week 13 of the study.

Trial Locations (1)

48109

RECRUITING

University of Michigan, Ann Arbor

All Listed Sponsors
collaborator

Commonwealth Diagnostics International, Inc.

UNKNOWN

lead

University of Michigan

OTHER

NCT03729271 - Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea | Biotech Hunter | Biotech Hunter